Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BrainAurora Medical Technology Limited ( (HK:6681) ) just unveiled an update.
BrainAurora Medical Technology reported strong top-line momentum for 2025, with revenue jumping 79.9% year-on-year to RMB220.05 million, driven by rapid adoption of its digital therapeutics platform and expanding hospital collaborations. Despite this growth, the company’s loss widened to RMB316.36 million, reflecting continued heavy investment in technology, product development and market expansion, while user engagement metrics and partner hospital numbers demonstrated robust operational traction.
Usage of BrainAurora’s home-based DTx system surged, with total patient sessions climbing from about 1.8 million in 2024 to roughly 3.3 million in 2025, and average monthly active users nearly doubling alongside longer daily usage times. The group also advanced its core product pipeline, notably progressing clinical research on its Dyslexia Assisted Recovery Training Software, aiming to complete registration studies and secure regulatory approval over the next two years, setting the stage for commercialization and potentially reinforcing its position in AI-enabled cognitive rehabilitation.
The most recent analyst rating on (HK:6681) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on BrainAurora Medical Technology Limited stock, see the HK:6681 Stock Forecast page.
More about BrainAurora Medical Technology Limited
BrainAurora Medical Technology Limited is a Cayman Islands–incorporated medical technology company focused on digital therapeutics (DTx) solutions, particularly AI-driven neurological and cognitive rehabilitation tools delivered via home-use systems and hospital partnerships. Its products target a growing user base in China through collaborations with over 200 hospitals, with strong footprints in regions such as the Pearl River Delta, Beijing-Tianjin-Hebei, Sichuan, and Henan, supporting nationwide scaling of its AI digital health management platform.
Average Trading Volume: 26,042,302
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.73B
Find detailed analytics on 6681 stock on TipRanks’ Stock Analysis page.